MedAvail Reports Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

MedAvail Holdings, Inc. (Nasdaq: MDVL) reported Q4 and full-year 2021 financial results, highlighting a total revenue of $7.3 million for Q4, with Retail Pharmacy Services revenue increasing 170% to $6.8 million. However, Pharmacy Technology revenue declined by 24%. The company recorded a net loss of $12.6 million for Q4, compared to a loss of $12.1 million in the prior year. For full-year 2021, total revenue reached $22.1 million, with a net loss of $43.8 million. Looking forward, MedAvail expects Q1 2022 revenue to exceed $8.8 million, more than double year-over-year.

Positive

• Retail Pharmacy Services revenue increased 170% in Q4 2021.
• Cumulative MedCenter deployments grew 76% to 81 total deployments.
• Q1 2022 revenue guidance of $8.8 million indicates more than 100% growth YoY.

Negative

• Pharmacy Technology revenue decreased 24% in Q4 2021.
• Net loss widened to $43.8 million for full-year 2021 from $26.8 million in 2020.
• Adjusted EBITDA loss expanded to $39.6 million in 2021 versus $23.8 million in 2020.

MISSISSAUGA, Ontario & PHOENIX--(BUSINESS WIRE)-- MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today reported financial results for the three months and full year ended December 31, 2021.

“I am excited to have joined MedAvail at a pivotal time when I believe that there is a tremendous need and a rising demand in pharmacy services for our technology and pharmacy solutions. Since joining MedAvail, my confidence in our business has only strengthened further,” said Mark Doerr, Chief Executive Officer of MedAvail. “As we look ahead to 2022, I believe that we are strongly positioned with expansion in dispensing deployments and partnerships well underway and a clear roadmap seeking to deliver profitable and sustainable growth over the long-term.”

Fourth Quarter 2021 Financial and Operational Highlights

All comparisons, unless otherwise noted, are to the three months ended December 31, 2020.

• Total revenue was $7.3 million
• Total revenue by segment
  • Retail Pharmacy Services revenue increased 170% to $6.8 million
  • Pharmacy Technology revenue decreased 24% to $0.4 million
• Net loss was $12.6 million compared to a net loss of $12.1 million
• Adjusted EBITDA loss of $10.9 million compared to $8.9 million
• Cash, and cash equivalents of $19.7 million as of December 31, 2021

Full Year 2021 Financial and Operational Highlights

All comparisons, unless otherwise noted, are to the twelve months ended December 31, 2020.

• Total revenue was $22.1 million
• Total revenue by segment
  • Retail Pharmacy Services revenue increased 161% to $20.2 million
  • Pharmacy Technology revenue decreased 69% to $1.9 million. Total revenue for the third quarter of 2020 included a non-recurring benefit of $4.7 million recognized in conjunction with a commercial agreement from 2018; excluding this benefit, Pharmacy Technology revenue increased 27%.
• 81 MedCenter total net cumulative deployments compared to 46 MedCenter total net cumulative deployments, representing 76% growth
  • 68 MedCenter total net dispensing deployments compared to 38 total MedCenter net dispensing deployments, representing 79% growth
• Net loss was $43.8 million compared to a net loss of $26.8 million
• Adjusted EBITDA loss of $39.6 million compared to $23.8 million

Financial Outlook

MedAvail expects total revenue for the first quarter of 2022 to be in excess of $8.8 million, which represents more than double its total revenue in the same period in 2021. The company expects adjusted gross margin improvement in the first quarter of 2022 compared to the fourth quarter of 2021.

Conference Call

MedAvail will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, March 24, 2022, to discuss its fourth quarter and full year 2021 financial results. A webcast of the conference call can be accessed at https://investors.medavail.com. The webcast will be archived and available for replay for at least 90 days after the event.

Definition of Key Metrics

Dispensing Deployments

We define dispensing deployments as deployments that are live, that is, have payer network acceptance, pharmacy board approvals and trained clinical staff or clinical account managers. Moreover, we work closely with the state boards of pharmacy and our clinic partners to reduce the time to progress from deployment to becoming dispensing deployments, which generally ranges from 4 to 12 weeks.

About MedAvail

MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes. Learn more at www.medavail.com.

Non-GAAP Financial Measures

MedAvail refers to certain financial measures that are not recognized under U.S. generally accepted accounting principles ("GAAP") in this press release, including adjusted EBITDA. See the schedules to this press release for additional information and reconciliations of such non-GAAP financial measures.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," "project," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding MedAvail's business strategy and market opportunity; potential future revenue projections and expectations for growth and profitability; expansion plans; margin improvement; and customer partnerships. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of MedAvail's management and are not predictions of actual performance. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to risks discussed under the heading "Risk Factors" in both MedAvail’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2021, and its Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2021, and other filings MedAvail makes with the SEC in the future. Additional information is also set forth in MedAvail’s Annual Report on Form 10-K for the year ended December 31, 2021 to be filed with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and MedAvail specifically disclaims any obligation to update these forward-looking statements.

SOURCE MedAvail Holdings, Inc.

MEDAVAIL HOLDINGS, INC.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per-share amounts)
(Unaudited)
	Three Months Ended December 31,								Years Ended December 31,
	2021				2020 (1)				2021				2020 (1)
Revenue:
Pharmacy and hardware revenue	$	6,954			$	3,009			$	21,119			$	10,596
Service revenue		326				91				1,010				3,372
Total revenue		7,280				3,100				22,129				13,968
Cost of products sold and services:
Pharmacy and hardware cost of products sold		7,562				3,250				21,306				8,593
Service costs		80				96				506				212
Total cost of products sold and services		7,642				3,346				21,812				8,805
Operating expense:
Pharmacy operations		4,068				2,195				13,496				6,146
General and administrative		5,544				5,795				22,277				15,863
Selling and marketing		2,148				1,206				7,204				3,283
Research and development		248				150				849				682
Merger expenses		—				2,084				—				4,691
Total operating expense		12,008				11,430				43,826				30,665
Operating loss		(12,370	)			(11,676	)			(43,509	)			(25,502	)
Other income (loss), net		—				(118	)			206				(110	)
Interest income		5				28				79				43
Interest expense		(261	)			(330	)			(589	)			(1,241	)
Loss before income taxes		(12,626	)			(12,096	)			(43,813	)			(26,810	)
Income tax expense		—				—				(2	)			—
Net loss	$	(12,626	)		$	(12,096	)		$	(43,815	)		$	(26,810	)
Other comprehensive income (loss):
Foreign currency translation adjustment	$	—			$	24			$	—			$	22
Total comprehensive loss	$	(12,626	)		$	(12,072	)		$	(43,815	)		$	(26,788	)
Net loss per share - basic and diluted	$	(0.38	)		$	(0.71	)		$	(1.34	)		$	(4.69	)
Weighted average shares outstanding - basic and diluted		32,852				17,003				32,656				5,722

⁽¹⁾ Certain activity was reclassified to be consistent with the current presentation, see comparative tables that follow.

MEDAVAIL HOLDINGS, INC.
Operating Expense Reclassifications
(In thousands)
(Unaudited)
	Three Months Ended December 31, 2020
	Current presentation			As previously reported			Change
Pharmacy operations	$	2,195		$	2,033		$	162
General and administrative		5,795			6,019			(224	)
Selling and marketing		1,206			1,147			59
Research and development		150			149			1
	$	9,346		$	9,348		$	(2	)

	Year Ended December 31, 2020
	Current presentation			As previously reported			Change
Pharmacy operations	$	6,146		$	5,687		$	459
General and administrative		15,863			16,562			(699	)
Selling and marketing		3,283			3,043			240
	$	25,292		$	25,292		$	—

MEDAVAIL HOLDINGS, INC.
Consolidated Condensed Balance Sheets
(In thousands, except share and per-share amounts)
(Unaudited)
	December 31,
	2021				2020
Assets
Current assets:
Cash and cash equivalents	$	19,689			$	57,936
Restricted cash		400				60
Accounts receivable, net		1,189				1,520
Inventories		3,916				2,817
Prepaid expenses and other current assets		2,191				1,534
Total current assets		27,385				63,867
Property, plant and equipment, net		5,692				3,795
Right-of-use assets		2,538				1,239
Other assets		228				203
Intangible assets, net		2,300				227
Total assets	$	38,143			$	69,331
Liabilities and Shareholders’ Equity (Deficit)
Current liabilities:
Accounts payable and accrued liabilities	$	6,740			$	4,512
Short-term debt		—				2,161
Deferred revenue		83				275
Current portion of lease obligations		682				665
Total current liabilities		7,505				7,613
Long-term debt		9,538				—
Long-term portion of lease obligations		2,027				651
Total liabilities		19,070				8,264
Commitments and contingencies
Stockholders' equity (deficit):
Common shares ($0.001 par value, 100,000,000 shares authorized, 32,902,048 and 31,816,020 shares issued and outstanding at December 31, 2021 and 2020, respectively)		33				32
Warrants		1,373				2,614
Additional paid-in-capital		216,685				213,624
Accumulated other comprehensive loss		(6,928	)			(6,928	)
Accumulated deficit		(192,090	)			(148,275	)
Total shareholders’ equity		19,073				61,067
Total liabilities and shareholders’ equity	$	38,143			$	69,331

MEDAVAIL HOLDINGS, INC.
Supplemental Financial Information - Segments
(In thousands)
(Unaudited)
	Retail Pharmacy Services				Pharmacy Technology				Total
Three Months Ended December 31, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	6,846			$	—			$	6,846
Hardware		—				—				—
Subscription		—				108				108
Total pharmacy and hardware revenue		6,846				108				6,954
Service revenue:
Software integration		—				—				—
Software		—				134				134
Maintenance and support		—				47				47
Installation		—				—				—
Professional services and other		—				145				145
Total service revenue		—				326				326
Total revenue		6,846				434				7,280
Cost of products sold and services (1)		6,901				741				7,642
Gross profit	$	(55	)		$	(307	)			(362	)

⁽¹⁾ The pharmacy technology segment includes a provision for inventory of $626 thousand.

	Retail Pharmacy Services				Pharmacy Technology				Total
Three Months Ended December 31, 2020
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	2,532			$	—			$	2,532
Hardware		—				353				353
Subscription		—				124				124
Total pharmacy and hardware revenue		2,532				477				3,009
Service revenue:
Software integration		—				—				—
Software		—				20				20
Maintenance and support		—				19				19
Installation		—				27				27
Professional services and other		—				25				25
Total service revenue		—				91				91
Total revenue		2,532				568				3,100
Cost of products sold and services (1)		2,685				661				3,346
Gross profit	$	(153	)		$	(93	)		$	(246	)

⁽¹⁾ The retail pharmacy services and pharmacy technology segments include provisions for inventory of $173 thousand and $179 thousand, respectively.

MEDAVAIL HOLDINGS, INC.
Supplemental Financial Information - Segments
(In thousands)
(Unaudited)
	Retail Pharmacy Services			Pharmacy Technology			Total
Year Ended December 31, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	20,203		$	—		$	20,203
Hardware		—			470			470
Subscription		—			446			446
Total pharmacy and hardware revenue		20,203			916			21,119
Service revenue:
Software integration		—			—			—
Software		—			259			259
Maintenance and support		—			161			161
Installation		—			39			39
Professional services and other		—			551			551
Total service revenue		—			1,010			1,010
Total revenue		20,203			1,926			22,129
Cost of products sold and services (1)		20,031			1,781			21,812
Gross profit	$	172		$	145		$	317

⁽¹⁾ The pharmacy technology segment includes a provision for inventory of $626 thousand.

	Retail Pharmacy Services				Pharmacy Technology (1)			Total
Year Ended December 31, 2020
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	7,728			$	—		$	7,728
Hardware		—				2,401			2,401
Subscription		—				467			467
Total pharmacy and hardware revenue		7,728				2,868			10,596
Service revenue:
Software integration		—				3,168			3,168
Software		—				44			44
Maintenance and support		—				58			58
Installation		—				55			55
Professional services and other		—				47			47
Total service revenue		—				3,372			3,372
Total revenue		7,728				6,240			13,968
Cost of products sold and services (2)		7,744				1,061			8,805
Gross profit	$	(16	)		$	5,179		$	5,163

⁽¹⁾ Includes $1.5 million of hardware sales and $3.2 million of software integration sales associated with a non-recurring commercial agreement.
⁽²⁾ The retail pharmacy services and pharmacy technology segments include provisions for inventory of $250 thousand and $179 thousand, respectively.

Non-GAAP Financial Measures

To supplement our consolidated condensed financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: EBITDA, and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We define Adjusted EBITDA for a particular period as net (loss) income before interest, taxes, depreciation and amortization, and as further adjusted for non-recurring revenue from a commercial agreement, inventory adjustment, merger-related expenses, and stock-based compensation expense.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results, like one-time transaction costs related to the reverse merger. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and liquidity as well as comparisons to our competitors' operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.

There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.

MEDAVAIL HOLDINGS, INC.
Reconciliation of GAAP to Non-GAAP Measures
(In thousands)
(unaudited)
	Three Months Ended December 31,						Years Ended December 31,
	2021			2020			2021			2020
Net loss	(12,626	)		(12,096	)		(43,815	)		(26,810	)
Adjustments to calculate EBITDA:
Interest income	(5	)		(28	)		(79	)		(43	)
Interest expense	261			330			589			1,241
Income tax expense	—			—			2			—
Depreciation and amortization (1)	569			298			1,827			1,089
EBITDA	(11,801	)		(11,496	)		(41,476	)		(24,523	)
Adjustments as follows:
Inventory adjustment (2)	626			352			626			429
Non-recurring commercial agreement (3)	—			—			—			(4,729	)
Merger expenses	—			2,084			—			4,691
Share-based compensation expense	257			155			1,205			380
Adjusted EBITDA	(10,918	)		(8,905	)		(39,645	)		(23,752	)

⁽¹⁾ Excludes $203 thousand and $750 thousand of operating lease amortization for the three months and year ended December 31, 2021, respectively.
⁽²⁾ Includes inventory cost adjustments.
⁽³⁾ The year ended December 31, 2020 includes $1.5 million of hardware sales and $3.2 million of software integration revenue associated with a non-recurring commercial agreement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005933/en/

Investor Relations

Caroline Paul

Gilmartin Group

ir@medavail.com

Source: MedAvail Holdings Inc.

FAQ

What were MedAvail's Q4 2021 financial results?

MedAvail reported total revenue of $7.3 million in Q4 2021, with a net loss of $12.6 million.

How did MedAvail's revenue grow in 2021?

For full-year 2021, MedAvail recorded total revenue of $22.1 million, with Retail Pharmacy Services revenue increasing 161%.

What is MedAvail's outlook for Q1 2022?

MedAvail expects Q1 2022 revenue to exceed $8.8 million, representing more than double its revenue in the same period of 2021.

What was the adjusted EBITDA loss for MedAvail in 2021?

MedAvail's adjusted EBITDA loss was $39.6 million for the full-year 2021.